# **Chapter 10 Subdural Hematomas in Adults and Children**



**Sinan Sağıroğlu and Mehmet Turgut**

## **10.1 Introduction**

Subdural hematoma (SDH) is one of the most common phenomena a neurosurgeon encounters. Since ancient times, trephination has been performed to relieve the sick of their symptoms. While craniotomy is still the modality of choice for SDH, the search for a better solution is a never-ending endeavor. Acute (aSDH) and chronic (cSDH) forms of the hematoma have different pathophysiology; hence, different treatment approaches are required. Craniotomy or craniectomy may be the required intervention for aSDH. For cSDH, twist-drill craniostomy (TDC), burr-hole craniostomy (BHC), and middle meningeal artery (MMA) embolization are various medical treatment options developed and researched to better manage the disease and reduce the cost of medical expenses. Here we present current treatment options for SDH.

S. Sağıroğlu

M. Turgut  $(\boxtimes)$ 

© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023

Department of Neurosurgery, Aydın Adnan Menderes University School of Medicine, Efeler, Aydın, Turkey

Department of Neurosurgery, Aydın Adnan Menderes University School of Medicine, Efeler, Aydın, Turkey

Department of Histology and Embryology, Aydın Adnan Menderes University Health Sciences Institute, Efeler, Aydın, Turkey

C. Di Rocco (ed.), *Advances and Technical Standards in Neurosurgery*, Advances and Technical Standards in Neurosurgery 46, [https://doi.org/10.1007/978-3-031-28202-7\\_10](https://doi.org/10.1007/978-3-031-28202-7_10#DOI)

# **10.2 Surgical Management of Subdural Hematoma in Adult Population**

An aSDH develops after a traumatic brain injury with an incidence of 31% [\[1\]](#page-8-0). About 69.8–74.3% of these patients are initially treated conservatively [[1,](#page-8-0) [2](#page-8-1)]. Of these patients, 6.5–11% required delayed surgery primarily due to the progression of the aSDH, and raised intracranial pressure (ICP) [\[1](#page-8-0), [2](#page-8-1)]. While the decision for surgery remains controversial and varies from one center to another, Brain Trauma Foundation guidelines are still used today [\[1\]](#page-8-0). The guideline states that an aSDH thickness  $>10$  mm or  $>5$  mm midline shift should be surgically evacuated regardless of GCS score. A patient with GCS <9 without the abovementioned criteria should be evaluated for surgery if the GCS score drops by 2 or more points during hospitalization or if there is an asymmetric dilated pupil or ICP of  $>20$  mmHg  $[3]$  $[3]$ .

A cSDH is usually a disease of the elderly with an incidence of 1.72–20.6 per 100,000 which increases with age [\[4](#page-9-1), [5\]](#page-9-2). There is consensus that large hematoma size, midline shift of more than  $5 \text{ mm}$  (Fig. [10.1](#page-1-0)), the disappearance of the basal cisterns, and a neurologic defcit are indications for surgery [[6\]](#page-9-3). Contrary to aSDH, cSDH is a process that develops over time and may be silent for some time before the onset of the symptoms [[4\]](#page-9-1).

<span id="page-1-0"></span>

**Fig. 10.1** T1-weighted (**a**), T2\*-GRE (**b**), and CT (**c**) images of a homogenous iso-dense cSDH with acute components on the frontal pole of the hematoma. Large hematoma volume and midline shift support surgical intervention. Hemosiderin staining is shown along the inner membrane of cSDH on T2\*-GRE (white arrows)

# *10.2.1 Craniotomy, Minicraniotomy, and Endoscope-Assisted Surgery*

A craniotomy is the main surgical treatment for aSDH. Surgery is useful for thick clot removal, possibly localizing and managing the source of the bleed and, if necessary, converting to craniectomy to relieve potential raised ICP, since most of the aSDH are a result of trauma. Bleeding is due to ruptured bridging veins or cortical arteries [\[7](#page-9-4)]. The craniotomy must encompass the acute hematoma borders as much as possible. The surgeon should avoid the superior sagittal sinus, and expose inferiorly to near the base of the temporal fossa including the greater wing of the sphenoid bone. A large  $12 \times 15$  cm frontotemporoparietal craniectomy is recommended for severe traumatic brain injury [\[8](#page-9-5)]. The dura is incised in a starlike fashion. The hematoma is removed using a combination of suction, irrigation, and forceps with careful traction. Irrigation is a powerful tool for hematoma removal. After hematoma evacuation, careful inspection of the surface of the brain may reveal the bleeding origin. Bleeding is controlled with bipolar electrocautery or, preferably, with an absorbable hemostatic agent. A subdural soft drain may be placed if the irrigation fuid is not clear and the origin of the bleeding site cannot be visualized. The dura is sutured closed in a watertight fashion, and dural tenting sutures are placed circumferentially to prevent developing an epidural hematoma. The bone fap is replaced with plates and screws. Subgaleal drain placement and standard closure techniques are followed.

Minicraniotomy with endoscope-assisted surgery is another recent technique developed for treating the elderly since conventional surgery for both aSDH and cSDH can have an unfavorable outcome [\[9](#page-9-6)]. The rationale for this approach is the removal of the hematoma and identifying the source of the bleeding under local anesthesia in a patient with a high risk for general anesthesia or a major surgical intervention.

The standard craniotomy procedure is performed over the thickest part of the hematoma, with a 2–5 cm diameter craniotomy. A recent cadaveric study on craniotomy locations of the minicraniotomy for the endoscopic operations found a 3-cmdiameter craniotomy over the most convex point of the parietal bone between the superior temporal line and the mid-pupillary line provides for optimal reach with a rigid endoscope. Yet the authors state that a minimum of a 6 mm subdural space is needed to avoid cortical damage [[10\]](#page-9-7). A fexible endoscope may provide a better view compared to a rigid endoscope, but this has little meaning if the other tools cannot reach to evacuate the hematoma [\[9](#page-9-6)]. The dura is incised in a starlike fashion, and hematoma removal using suction, irrigation, and forceps is ensued. Then, the endoscope is used to visualize and remove as much as possible of the rest of the hematoma with the same techniques. The source of the bleed is controlled with bipolar electrocautery if possible. Endoscope-assisted aSDH removal is an alterna-tive technique that may be beneficial in select patients [\[9](#page-9-6)].

Craniotomy or endoscope-assisted minicraniotomy is reserved for patients with extensive membrane formations, calcifed hematomas (Fig. [10.2](#page-3-0)), or recurrent

<span id="page-3-0"></span>

Fig. 10.2 CT image of a calcified/ossified cSDH, which requires craniotomy if the patient is symptomatic

bleeding [[6,](#page-9-3) [11](#page-9-8), [12\]](#page-9-9). Some studies report increased mortality or poor outcome for older patients with surgery [[11,](#page-9-8) [13](#page-9-10), [14\]](#page-9-11). Hence, the inclination toward minimal intervention has resulted in the development of safe and alternative techniques for cSDH treatment.

## *10.2.2 Burr-Hole and Twist-Drill Craniostomies*

A burr-hole is described as a 10–30 mm craniostomy of the skull [\[15](#page-9-12)]. The hole must be drilled over the thickest part of the hematoma, typically in the parietal bone, slightly above the superior temporal line. A second burr-hole is preferable for large hematomas, usually in the frontal bone. The patient must be positioned so the frontal hole should be the highest point of the head. After the holes are prepared, bony bleeding must be waxed, and the dura is coagulated with bipolar cautery. In large hematomas and typically patients with a high Markwalder Grading Score (MGS), intracranial pressure (ICP) may be so high that a liquid hematoma may expel itself. The surgeon must avoid a sudden pressure drop and rapid expansion of the brain to avoid axonal injury. The dura and outer membranes are incised starting from the frontal hole; dark purple-red hematoma and the typical "engine oil" appearing fuid are evacuated. Irrigation of the hematoma with a soft catheter may be benefcial due to lower recurrence rates, without signifcant evidence [\[16](#page-9-13)]. Thorough irrigation is preferred without intradural cannulation in our center due to the reduced risk of the drain clogging with a clot and increased risk of parenchymal injury from blind insertion of the catheter. External membrane and dural leafets are cauterized to

avoid recurrence. The parietal hole is closed frst with a mesh or gel foam, and the galea and skin are sutured. The subdural space is flled with saline, and a subdural or subgaleal drain is placed before the galea and skin closure. Drainage after hematoma evacuation is recommended and reduces the recurrence of cSDH by 60% [\[6](#page-9-3), [16\]](#page-9-13). A subperiosteal drain is as effective as a subdural drain and has a potentially lower complication rate [\[6](#page-9-3)]. The order of closure of the holes and their flling with saline is meant to reduce air entrapment which may prevent brain re-expansion.

Twist-drill craniostomy is described as a quick and bedside intervention performed under local anesthesia. Under local anesthesia, approximately a 1 cm incision over the thickest part of the hematoma and drilling of the bone with a 45° angle to the surface of the bone are performed. The dura and the outer membrane are perforated, and the subdural cannula is inserted, which is connected to a reservoir for passive drainage [\[17](#page-9-14)]. Later modifcations of the technique abandon intradural cannulation and instead place a hollow screw, YL-1 needle, or a subdural evacuating port system (SEPS) through the hole. This approach lowered the complication rates of the procedure and was deemed successful as frst-line treatment as it is minimally invasive, requires no general anesthesia, and does not require occupying the operating room. TDC has a similar success and recurrence rate as BHC, with approximately half the complication rate of BHC [[18\]](#page-9-15).

Both BHC and TDC are effective in CSDH evacuation. The advantages of BHC are direct visualization and possible intervention of multiple membranes of the hematomas with subacute components or septations, which may occlude the TDC drain and result in unsuccessful hematoma resorption. Some studies report BHC to have a lower recurrence rate, yet some have found no significant difference [[6,](#page-9-3) [19\]](#page-9-16). TDC on the other hand is easy to perform, suitable for patients with a high risk for general anesthesia and those with shorter hospitalization time [\[18](#page-9-15), [20](#page-9-17)].

# **10.3 Embolization of Middle Meningeal Artery for Chronic Subdural Hematoma**

It is hypothesized that the external membrane of cSDH is the reason for maintaining and expansion of the hematoma [\[21](#page-9-18)]. Recent studies propose eliminating the arterial supply of the tissue by embolizing MMA which might halt hematoma expansion and facilitate resolution [[21\]](#page-9-18). MMA embolization signifcantly reduces the recurrence of cSDH compared to serial neuroimaging or surgical intervention [\[22](#page-9-19)].

Under local anesthesia, after femoral or radial arterial catheterization, a catheter is placed in the proximal external carotid artery. Selective angiography reveals the internal maxillary artery and MMA. A microcatheter is advanced into the MMA with a guidewire. Anastomoses of MMA branches with the ophthalmic artery and inferolateral trunk and anatomical variations of the artery must be kept in mind before the administration of the embolizing agent [[23\]](#page-9-20). Branches supplying the dura are selectively cannulated and embolized with liquid or particle embolic agents (Fig. [10.3](#page-5-0)).

<span id="page-5-0"></span>

**Fig. 10.3** Angiography demonstrating terminal branches of the left external carotid artery (**a**). MMA (asterisk) and superfcial temporal artery (black arrow) are shown. Superselective angiography demonstrates the frontal (asterisk), parietal (dotted arrow), and petrosal branch (curved arrow) of MMA (**b**). The occluded frontal branch of MMA with a liquid embolic agent (arrow) and coil embolization of the parietal branch (asterisk) (**c**) [\[24\]](#page-9-21)

While the technique is reserved for asymptomatic patients, since neurologic deterioration requires surgical intervention, MMA embolization is a promising treatment option. Several studies have found MMA embolization signifcantly reduces the recurrence rates of BHC and may be a viable frst-line intervention for patients with asymptomatic cSDH and several medical comorbidities [[6,](#page-9-3) [21,](#page-9-18) [22\]](#page-9-19).

## **10.4 Medical Management of Chronic Subdural Hematoma**

While surgical intervention is the primary approach to cSHD, in some patients surgery might not be a viable option due to comorbidities such as severe cardiac or pulmonary diseases. Surgical mortality and morbidity of patients with cSDH, which are typically in the elderly population, also support the initiative for nonsurgical treatment options. Patients with high surgical risk, with minor symptoms, and with an MGS score of 0–1 and those that refuse surgery are candidates for medical treatment [[6\]](#page-9-3). Regardless of whether surgery is performed or not, recent studies recommend medical treatment to reduce recurrence [\[25](#page-9-22)]. Several medical alternatives have been established for the treatment of CSDH.

## *10.4.1 Dexamethasone*

Neomembrane formation and leakage of blood or blood products from the neocapillaries of the membrane are the prominent theories for cSDH formation and maintenance [[26](#page-10-0)]. Dexamethasone (DXM) may be benefcial in the resolution of hematoma by inhibition of the immune response ergo and maturation of neomembrane [[27,](#page-10-1) [28\]](#page-10-2). A recent meta-analysis states that DXM is the best medication to prevent the recurrence of cSDH [[25](#page-9-22)]. However, an overall increase in mortality with DXM even with low doses might negate the potential benefts [\[28\]](#page-10-2). Recent studies recommend the use of DEX in low doses and for short duration [\[25,](#page-9-22) [28](#page-10-2)].

#### *10.4.2 Atorvastatin*

Atorvastatin (ATO), an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, has recently been established to reduce hematoma volume in cSDH through anti-infammatory effects [[28\]](#page-10-2). Recent meta-analyses support the effectiveness of low-dose ATO both as a frst-line treatment and to improve the effectiveness of the surgery [[25\]](#page-9-22). ATO is associated with good recovery [[28\]](#page-10-2). DEX has a synergistic effect with ATO where both drug levels increase in the hematoma and increase the anti-infammatory effects through macrophage regulation [[29\]](#page-10-3).

## *10.4.3 Tranexamic Acid*

Tranexamic acid (TXA) is a synthetic plasmin inhibitor that inhibits fbrinplasminogen bonding [\[30](#page-10-4)]. TXA is found to be the second most effective single treatment after DEX in preventing cSDH recurrence and also the second best treatment in reducing hematoma volume after ATO [\[25](#page-9-22), [28](#page-10-2)]. TXA has been shown to increase the incidence of epilepsy in a dose-relative manner indicating cautious use is advised [\[31](#page-10-5)].

## *10.4.4 Goreisan*

Goreisan (GRS) is an inhibitor of aquaporin-4 found on the outer membrane of the cSDH. Goreisan is theorized to prevent fuid infow into the cSDH resulting in the resolution of the hematoma [[32\]](#page-10-6). However, some recent studies found little to no effect in preventing the recurrence of SDH [\[25](#page-9-22), [30](#page-10-4)]. Harada et al. [\[33](#page-10-7)] found Goreisan to be effective in homogenous iso-dense type cSDH (Fig. [10.4\)](#page-7-0), and less effective in other types of the disease.

<span id="page-7-0"></span>

**Fig. 10.4** Nakaguchi classifcation of cSDH. Homogenous hypo-dense (**a**), homogenous isodense (**b**), homogenous hyperdense (**c**), laminar (**d**), separated (**e**), trabecular (**f**) [\[34,](#page-10-8) [35](#page-10-9)]

# **10.5 Surgical Management of Subdural Hematoma in Pediatric Population**

An aSDH is almost always associated with non-accidental traumatic injury in children [\[36](#page-10-10), [37\]](#page-10-11). Other causes are trauma, surgical complications, fetal SDH, traumatic birth, aneurysm, arachnoid cyst, hematological diseases causing coagulopathy, glutaric aciduria, galactosemia, and hypernatremia [[37\]](#page-10-11). Severe trauma may require conventional craniotomy/craniectomy and hematoma evacuation. If craniectomy is performed, future cranioplasty may be required due to physiologic growth of the skull and possible resorption of the bone fap [\[38](#page-10-12)].

If cSDH is seen in an infant, subdural tapping may be a viable option if the anterior fontanel is patent. The tapping point is the crossing of the mid-pupillary line and coronal suture of the anterior fontanel. The catheter is inserted approximately 1 cm posterior to the point and advanced subcutaneously and then turned 90° perpendicular to the skull. This subcutaneous advancement prevents cerebrospinal fuid leakage after tapping. Sudden decompression must be avoided.

External subdural drainage is an effective way to treat infantile cSDH [[39\]](#page-10-13). External drainage is an effective way for cSDH treatment but increases the risk of infection, and catheter obstruction may complicate the treatment [\[39](#page-10-13)]. Another common technique is the placement of subdural shunts for hygromas and cSDH [\[40](#page-10-14), [41\]](#page-10-15). Subdural to intraperitoneal or subdural to subgaleal shunts without a valve have been reported with success [\[40](#page-10-14), [41](#page-10-15)]. While subdural shunts are reported to

have lower recurrence rates than other procedures, a second surgery is almost always necessary for complications such as obstruction or infection or removal of the shunt after resolution of the hematoma [\[40](#page-10-14), [41](#page-10-15)]. Hyperdense hemorrhage on computed tomography (CT) suggests that blood products may cause shunt occlusion in the future, and alternative methods could be considered [\[42](#page-10-16)].

Multiple membranes on imaging may require BHC or minicraniotomy. The technique is similar to that described above. The use of drainage has been reported with mixed results, and BHC seems to have a higher recurrence rate in contrast to adults [\[43](#page-10-17), [44](#page-10-18)]. Minicraniotomy may be a better option in the pediatric population with a relatively lower recurrence rate, therefore fewer surgical interventions [\[44](#page-10-18)]. Creating a subgaleal pouch without using drainage may be a viable modifcation for lower recurrence rates in infants [\[45](#page-10-19)].

Low-dose dexamethasone and atorvastatin-combined treatment has been shown to resolve post-BDH recurrence in pediatric patients [\[46](#page-10-20)]. MMA embolization was also successfully demonstrated to be effective in treating recurred hematoma after BHC in an 18-month-old patient [[47\]](#page-10-21).

## **10.6 Conclusion**

There are extensive research and ample meta-analyses regarding SDH in adult and geriatric patients in the literature. Optimal surgical intervention must be decided on a case-by-case basis. Considerations must be made on multiple factors such as the etiology of the hematoma, age, comorbidities of the patient, and CT fndings. The optimal approach is still debatable, and recent advancements in the feld have created a stir in the community. Thanks to recent advances in the TDC technique, it appears to have a similar success and recurrence rate to BHC. MMA embolization or therapeutic medical options such as low-dose dexamethasone and atorvastatin in combination may preclude surgical intervention in select patients or can be used to improve surgical success rates.

The pediatric population and infants have different characteristics and success rates for the same procedures compared to adults. Hence, different approaches are often used. Unfortunately, reports in this area are scarce, and the quality of evidence is far lower than that found in adults. Further research in the feld is necessary for the development of standardized surgical guidelines.

## **References**

- <span id="page-8-0"></span>1. van Essen TA, Lingsma HF, Pisică D, et al. Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study. Lancet Neurol. 2022;21:620–31.
- <span id="page-8-1"></span>2. Bajsarowicz P, Prakash I, Lamoureux J, et al. Nonsurgical acute traumatic subdural hematoma: what is the risk? J Neurosurg. 2015;123:1176–83.
- <span id="page-9-0"></span>3. Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery. 2006;58:S16–24; discussion Si-iv.
- <span id="page-9-1"></span>4. Mekaj AY, Morina AA, Mekaj YH, et al. Surgical treatment of 137 cases with chronic subdural hematoma at the university clinical center of Kosovo during the period 2008-2012. J Neurosci Rur Pract. 2015;6:186–90.
- <span id="page-9-2"></span>5. Yang W, Huang J. Chronic subdural hematoma: epidemiology and natural history. Neurosurg Clin N Am. 2017;28:205–10.
- <span id="page-9-3"></span>6. Solou M, Ydreos I, Gavra M, et al. Controversies in the surgical treatment of chronic subdural hematoma: a systematic scoping review. Diagnostics. 2022;12:2060.
- <span id="page-9-4"></span>7. Miller JD, Nader R. Acute subdural hematoma from bridging vein rupture: a potential mechanism for growth. J Neurosurg. 2014;120:1378–84.
- <span id="page-9-5"></span>8. Hawryluk GWJ, Rubiano AM, Totten AM, et al. Guidelines for the management of severe traumatic brain injury: 2020 Update of the decompressive craniectomy recommendations. Neurosurgery. 2020;87:427–34.
- <span id="page-9-6"></span>9. Spencer RJ, Manivannan S, Zaben M. Endoscope-assisted techniques for evacuation of acute subdural haematoma in the elderly: the lesser of two evils? A scoping review of the literature. Clin Neurol Neurosurg. 2021;207:106712.
- <span id="page-9-7"></span>10. Yakar F, Egemen E, Dere UA, et al. Subdural hematoma evacuation via rigid endoscopy system: a cadaveric study. J Craniofac Surg. 2020;32:e402.
- <span id="page-9-8"></span>11. Fomchenko EI, Gilmore EJ, Matouk CC, et al. Management of subdural hematomas: Part II. Surgical management of subdural hematomas. Curr Treat Options Neurol. 2018;20:34.
- <span id="page-9-9"></span>12. Turgut M, Akhaddar A, Turgut AT. Calcifed or ossifed chronic subdural hematoma: a systematic review of 114 cases reported during last century with a demonstrative case report. World Neurosurg. 2020;134:240–63.
- <span id="page-9-10"></span>13. Manivannan S, Spencer R, Marei O, et al. Acute subdural haematoma in the elderly: to operate or not to operate? A systematic review and meta-analysis of outcomes following surgery. BMJ Open. 2021;11:e050786.
- <span id="page-9-11"></span>14. Shlobin NA, Kedda J, Wishart D, et al. Surgical management of chronic subdural hematoma in older adults: a systematic review. J Gerontol A. 2021;76:1454–62.
- <span id="page-9-12"></span>15. Weigel R. Outcome of contemporary surgery for chronic subdural haematoma: evidence based review. J Neurol Neurosurg Psychiatry. 2003;74:937–43.
- <span id="page-9-13"></span>16. Liu W, Bakker NA, Groen RJM. Chronic subdural hematoma: a systematic review and metaanalysis of surgical procedures: a systematic review. J Neurosurg. 2014;121:665–73.
- <span id="page-9-14"></span>17. Tabaddor K, Shulmon K. Defnitive treatment of chronic subdural hematoma by twist-drill craniostomy and closed-system drainage. J Neurosurg. 1977;46:220–6.
- <span id="page-9-15"></span>18. Wei Z, Jiang H, Wang Y, Wang C. Effect of Twist-Drill Craniostomy with hollow screws for evacuation of chronic subdural hematoma: a meta-analysis. Front Neurol. 2022;12:811873.
- <span id="page-9-16"></span>19. Yagnik KJ, Goyal A, Van Gompel JJ. Twist drill craniostomy vs burr hole drainage of chronic subdural hematoma: a systematic review and meta-analysis. Acta Neurochir. 2021;163:3229–41.
- <span id="page-9-17"></span>20. Hoffman H, Jalal MS, Bunch KM, Chin LS. Management of chronic subdural hematoma with the subdural evacuating port system: systematic review and meta-analysis. J Clin Neurosci. 2021;86:154–63.
- <span id="page-9-18"></span>21. Ban SP, Hwang G, Byoun HS, et al. Middle meningeal artery embolization for chronic subdural hematoma. Radiology. 2018;286:992–9.
- <span id="page-9-19"></span>22. Ironside N, Nguyen C, Do Q, et al. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis. J NeuroIntervent Surg. 2021;13:951–7.
- <span id="page-9-20"></span>23. Bonasia S, Smajda S, Ciccio G, Robert T. Middle meningeal artery: anatomy and variations. AJNR Am J Neuroradiol. 2020;41:1777–85.
- <span id="page-9-21"></span>24. Zyck S, Babu H. Middle meningeal artery embolization for chronic subdural hematomas. In: Turgut M, Akhaddar A, Hall WA, Turgut AT, editors. Subdural hematoma. Cham: Springer International Publishing; 2021. p. 391–9.
- <span id="page-9-22"></span>25. Yu W, Chen W, Jiang Y, et al. Effectiveness comparisons of drug therapy on chronic subdural hematoma recurrence: a bayesian network meta-analysis and systematic review. Front Pharmacol. 2022;13:845386.
- <span id="page-10-0"></span>26. Edlmann E, Giorgi-Coll S, Whitfeld PC, et al. Pathophysiology of chronic subdural haematoma: infammation, angiogenesis and implications for pharmacotherapy. J Neuroinfammation. 2017;14:108.
- <span id="page-10-1"></span>27. Fan Y-S, Wang B, Wang D, et al. Atorvastatin combined with low-dose dexamethasone for vascular endothelial cell dysfunction induced by chronic subdural hematoma. Neural Regen Res. 2021;16:523.
- <span id="page-10-2"></span>28. Wang X, Song J, He Q, You C. Pharmacological treatment in the management of chronic subdural hematoma. Front Aging Neurosci. 2021;13:684501.
- <span id="page-10-3"></span>29. Gong Z, Zhan D, Nie M, et al. Dexamethasone enhances the effcacy of atorvastatin in inhibiting excessively infammation-induced abnormal angiogenesis by regulating macrophages. J Neuroinfammation. 2021;18:203.
- <span id="page-10-4"></span>30. Yamada T, Natori Y. Prospective study on the effcacy of orally administered tranexamic acid and Goreisan for the prevention of recurrence after chronic subdural hematoma burr hole surgery. World Neurosurg. 2020;134:e549–53.
- <span id="page-10-5"></span>31. Lin Z, Xiaoyi Z. Tranexamic acid-associated seizures: a meta-analysis. Seizure. 2016;36:70–3.
- <span id="page-10-6"></span>32. Utsuki S, Oka H, Kijima C, et al. Role of saireito in postoperative chronic subdural hematoma recurrence prevention. J Tradit Med. 2012;29(3):137.
- <span id="page-10-7"></span>33. Harada Y, Yoshida K, Nojiri S, et al. Identifcation of chronic subdural hematoma types most responsive to Goreisan, Kampo medicine: a retrospective study. J Clin Neurosci. 2020;78:198–202.
- <span id="page-10-8"></span>34. Nakaguchi H, Tanishima T, Yoshimasu N. Factors in the natural history of chronic subdural hematomas that infuence their postoperative recurrence. J Neurosurg. 2001;95:256–62.
- <span id="page-10-9"></span>35. You W, Zhu Y, Wang Y, et al. Prevalence of and risk factors for recurrence of chronic subdural hematoma. Acta Neurochir. 2018;160:893–9.
- <span id="page-10-10"></span>36. Jayawant S, Rawlinson A, Gibbon F, et al. Subdural haemorrhages in infants: population based study. BMJ. 1998;317:4.
- <span id="page-10-11"></span>37. Kemp AM. Investigating subdural haemorrhage in infants. Arch Dis Child. 2002;86:98–102.
- <span id="page-10-12"></span>38. Beez T, Munoz-Bendix C, Ahmadi SA, et al. From decompressive craniectomy to cranioplasty and beyond—a pediatric neurosurgery perspective. Childs Nerv Syst. 2019;35:1517–24.
- <span id="page-10-13"></span>39. Lin C-L, Hwang S-L, Su Y-F, et al. External subdural drainage in the treatment of infantile chronic subdural hematoma. J Trauma Inj Infect Crit Care. 2004;57:104–7.
- <span id="page-10-14"></span>40. Blauwblomme T, Di Rocco F, Bourgeois M, et al. Subdural to subgaleal shunts: alternative treatment in infants with nonaccidental traumatic brain injury? J Neurosurg Pediatr. 2015;15:306–9.
- <span id="page-10-15"></span>41. Vinchon M, Noulé N, Soto-Ares G, Dhellemmes P. Subduroperitoneal drainage for subdural hematomas in infants: results in 244 cases. J Neurosurg. 2001;95:249–55.
- <span id="page-10-16"></span>42. Kurschel S, Puget S, Bourgeois M, et al. Factors infuencing the complication rate of subduroperitoneal shunt placement for the treatment of subdural hematomas in infants. J Neurosurg. 2007;106:172–8.
- <span id="page-10-17"></span>43. Deora H, Mishra A, Gupta R, et al. Paediatric chronic subdural haematoma: what are the predisposing factors and outcomes in management of these cases? Childs Nerv Syst. 2022;38:123–32.
- <span id="page-10-18"></span>44. Klimo P, Matthews A, Lew SM, et al. Minicraniotomy versus bur holes for evacuation of chronic subdural collections in infants—a preliminary single-institution experience: clinical article. J Neurosurg Pediatr. 2011;8:423–9.
- <span id="page-10-19"></span>45. Palmer AW, Albert GW. Minicraniotomy with a subgaleal pocket for the treatment of subdural fuid collections in infants. J Neurosurg Pediatr. 2019;23:480–5.
- <span id="page-10-20"></span>46. Huang J, Li L, Zhang J, et al. Treatment of relapsed chronic subdural hematoma in four young children with atorvastatin and low-dose dexamethasone. Pharmacotherapy. 2019;39:783–9.
- <span id="page-10-21"></span>47. Faber R, Feller CN, Gofman N, et al. Pediatric middle meningeal artery embolization for chronic subdural hematoma: a case report. Surg Neurol Int. 2021;12:239.